Orphan Drugs & Rare Diseases 2017 Americas
12 Sep,2017 - 14 Sep,2017
San Francisco, CA, USA
A Little Teaser
The global orphan drugs market is expected to grow at a steady CAGR of 11.43% from 2016 to 2022. At the current forecasted growth rate, the orphan drugs market is expected to grow from USD 111.87 billion in 2016 and become worth USD 214.14 billion by 2022.
The growth of the global orphan drugs market is increasing due to the growing rare diseases. Orphan diseases are rare in nature which means its occurrence rate is very low, but its prevalence rate is expected to increase in the forecasted period thereby increasing the demand of global orphan diseases market. There are around 7000 rare types of rare diseases and disorders, these numbers are increasing day by day. 80% of rare diseases are genetically originated and rest are result of infections, environmental causes and allergies. Around 50% of genetic diseases are in children’s, 30 % of children with rare diseases cannot live for more than 5 years. Rare diseases are one of the life-threatening diseases that kills millions of lives worldwide. Orphan drugs are the pharmaceutical agent that is specially developed for rare diseases. The prevalence rate of rare diseases are growing at a faster rate, the result in growing need of drugs to cure that diseases.
Paradigm Global Events is again proud to present our bi-annual Orphan Drugs & Rare Diseases Global Congress 2017 Americas. The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing, access and more. We look forward to having you be part of the event!
The two-day Congress will provide an interactive and intimate discussion and networking format led by key industry speakers with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.